Insmed reported $253.03M in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
BioMarin Pharmaceutical USD 333.64M 61.91M Sep/2026
Cytokinetics USD 113.14M 8.75M Sep/2026
DBV Technologies USD 15.8M 2.4M Sep/2026
Gilead Sciences USD 1.52B 70M Jun/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Insmed USD 253.03M 5.56M Sep/2026
Novartis USD 3.08B 58M Sep/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Sarepta Therapeutics USD 118.61M 11.01M Sep/2026
Ultragenyx Pharmaceutical USD 97M 9M Sep/2026
Vertex Pharmaceuticals USD 556.3M 25.9M Sep/2026